CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Cocrystal Pharma Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Cocrystal Pharma Inc
19805 N Creek Pkwy
Phone: (786) 459-1831p:786 459-1831 BOTHELL, WA  98011-8251  United States Ticker: COCPCOCP

Business Summary
Cocrystal Pharma, Inc., is a clinical stage biotechnology company. The Company focuses on discovering and developing novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. The Company focuses on developing and commercializing antiviral drug candidates for the treatment and prophylaxis of hepatitis C, influenza and norovirus. The Company uses computational methods to screen and design product candidates using its cocrystal structural information. The Company’s Hepatitis C Virus (HCV) Non-Nucleoside Polymerase Inhibitor CC-31244 is a pan-genotypic inhibitor of NS5B polymerase for the treatment of hepatitis C infection. The Company’s CC-42344 is a novel PB2 inhibitor for the treatment of influenza infection. The Company is also focused on identifying and developing nucleoside and non-nucleoside polymerase inhibitors for the treatment of Norovirus infections.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
IRA CQ
Score
Moody's
Rating
Fitch
Rating
DBRS
Rating
Morningstar
Rating
YesYes-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/201912/31/2018YesYes--Yes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board, Chief Executive Officer Gary L.Wilcox 71 2/1/2019 1/2/2014
President SamLee 56 11/25/2014 1/2/2014
Chief Financial Officer James J.Martin 50 5/30/2017 2/27/2017
5 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Cocrystal Discovery, Inc. 19805 N Creek Pkwy Bothell WA United States

Business Names
Business Name
BioZone Laboratories, Inc.
COCP
COCPD
5 additional Business Names available in full report.

General Information
Number of Employees: 10 (As of 4/1/2019)
Outstanding Shares: 31,621,000 (As of 9/30/2019)
Shareholders: 425
Stock Exchange: NASD
Federal Tax Id: 205978559
Fax Number: (302) 636-5454


Copyright © 2019 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, December 08, 2019